• aTyr Pharma outlined plans in first-quarter 2026 update to launch a new global Phase 3 study of efzofitimod in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, targeting an IND submission in June 2026.
• FDA feedback in a Type C meeting set a new development path following prior Phase 3 EFZO-FIT results, which were already reviewed with regulators.
• Trial aims to show efzofitimod can preserve lung function while improving patient-reported breathing-related health status, with dosing set once every three weeks over 54 weeks.
• Study design calls for up to 372 patients on stable background therapy, positioning the program for a renewed late-stage readout in a high-unmet-need interstitial lung disease segment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001339970-26-000030), on May 15, 2026, and is solely responsible for the information contained therein.